Medical weight management | New York
Wegovy tablets are an FDA-approved once-daily oral form of semaglutide for weight reduction in eligible adults and for reducing major cardiovascular events in adults with established cardiovascular disease and obesity or overweight. The pill was approved on December 22, 2025 and launched broadly in the United States on January 5, 2026. The tablet is not labeled for pediatric weight management or for MASH.
Wegovy tablets are FDA approved and commercially available in the United States. The current combined Wegovy prescribing information was revised in June 2026. This page describes evaluation and care coordination. A prescription, coverage, dispensing, teaching visit, or administration is never automatic.
The tablet indications cover adult weight reduction and adult cardiovascular risk reduction in the labeled populations. Wegovy injection has additional labeled uses, including pediatric obesity and noncirrhotic MASH with F2 to F3 fibrosis, that do not transfer to the tablet.
The clinician should confirm the adult indication, cardiovascular and weight history, current medicines, diabetes and eye history, gastrointestinal and gallbladder concerns, pregnancy plans, procedure plans, contraindications, and whether the daily fasting routine is practical.
Take the tablet once daily on an empty stomach in the morning with up to four ounces of water. Swallow it whole, then wait at least 30 minutes before eating, drinking, or taking other oral medicines. The label escalates through 1.5 mg, 4 mg, and 9 mg to a 25 mg maintenance dose.
Follow-up should address response, gastrointestinal effects, hydration, kidney concerns, blood glucose when relevant, retinopathy history, heart rate, hypersensitivity, gallbladder or pancreatitis symptoms, and absorption of important oral medicines.
A brand name is not enough to determine whether treatment is appropriate. The clinician must connect the label to the patient's diagnoses, current medicines, prior treatment, laboratory results, preferences, and coverage.
The clinician should confirm the adult indication, cardiovascular and weight history, current medicines, diabetes and eye history, gastrointestinal and gallbladder concerns, pregnancy plans, procedure plans, contraindications, and whether the daily fasting routine is practical.
Follow-up should address response, gastrointestinal effects, hydration, kidney concerns, blood glucose when relevant, retinopathy history, heart rate, hypersensitivity, gallbladder or pancreatitis symptoms, and absorption of important oral medicines.
Nao Medical must confirm the adult-only tablet pathway, fasting administration counseling, switching protocol, pharmacy and payer workflow, interaction review, and follow-up before offering this pathway.
Oral Wegovy and Wegovy injection share an active ingredient but not every indication, dose, or administration instruction. Switching between them follows specific label instructions and should be directed by the prescriber.
An evaluation may lead to another medicine, more testing, a referral, or no medication change.
The health plan and dispensing pharmacy make coverage and fulfillment decisions. Prior authorization may be required.
The clinic cards below show places to start an evaluation. They do not prove that a product is stocked, dispensed, taught, or administered at that site.
The sequence protects safety and keeps a product request from bypassing diagnosis, records, monitoring, access, or referral needs.
The clinician reviews weight history, prior treatment, current medicines, related conditions, pregnancy plans when relevant, and the patient's goals.
The visit addresses label criteria, contraindications, interactions, side effects, nutrition, activity, and whether another treatment path is more appropriate.
If a prescription is appropriate, the team discusses the dosage form, administration instructions, coverage process, and follow-up. Approval and supply are not guaranteed.
Follow-up considers response, tolerability, adherence, dose changes, related conditions, and whether treatment should continue or change.
Choose a nearby Nao Medical clinic as a starting point for evaluation or care coordination.
Capability boundary: these location cards do not establish that a medicine, device, laboratory test, injection, or specialty workflow is available at every site. Confirm the exact service before travel.
Bronx
932 E 174th St, Bronx, NY 10460
A place to begin evaluation and care coordination near West Farms, Crotona Park East, and nearby Bronx neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Queens
37-15 23rd Ave, Astoria, NY 11105
A place to begin evaluation and care coordination near Astoria, Ditmars, East Elmhurst, and nearby Queens neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Bronx
2063A Bartow Ave, Bronx, NY 10475
A place to begin evaluation and care coordination near Co-op City, Pelham Bay, Baychester, and nearby Bronx neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Brooklyn
341 Eastern Pkwy, Brooklyn, NY 11216
A place to begin evaluation and care coordination near Crown Heights, Prospect Heights, and nearby Brooklyn neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Long Island
232 W Old Country Rd, Hicksville, NY 11801
A place to begin evaluation and care coordination near Hicksville, Plainview, Bethpage, and nearby Nassau County communities. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Queens
80-10 Northern Blvd, Jackson Heights, NY 11372
A place to begin evaluation and care coordination near Jackson Heights, Elmhurst, Corona, and nearby Queens neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Queens
90-18 Sutphin Blvd, Jamaica, NY 11435
A place to begin evaluation and care coordination near Jamaica, Briarwood, Richmond Hill, and nearby Queens neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Queens
30-07 36th Ave, Astoria, NY 11106
A place to begin evaluation and care coordination near Long Island City, Astoria, Sunnyside, and nearby Queens neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Long Island
135 Mineola Blvd, Mineola, NY 11501
A place to begin evaluation and care coordination near Mineola, Garden City, Westbury, and nearby Nassau County communities. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Manhattan
259 1st Ave, New York, NY 10003
A place to begin evaluation and care coordination near StuyTown, the East Village, Gramercy, and nearby Manhattan neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Brooklyn
308 Graham Ave, Brooklyn, NY 11211
A place to begin evaluation and care coordination near Williamsburg, Greenpoint, Bushwick, and nearby Brooklyn neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Use these focused pages to compare options, prepare for an evaluation, and connect medication questions with broader care.
Review weekly injection, pediatric, Wegovy HD, and broader Wegovy questions.
Explore Nao Medical's broader weight-management program and treatment options.
Compare a different oral GLP-1 with different food and interaction instructions.
Review the injection-only liver indication without applying it to tablets.
Coordinate glucose-lowering treatment and hypoglycemia risk when diabetes is present.
Answers reflect the current official sources and the limited evaluation-and-coordination scope described on this page.
These sources support product identity, approval, current labeling, availability, and clinical boundaries. They do not prove Nao Medical site capability or health-plan coverage.
Current tablet and injection indications, dose escalation, switching, contraindications, and safety information.
Open official sourceFDA approval date, adult indications, and planned U.S. launch.
Open official sourceOfficial broad U.S. launch and pharmacy availability date.
Open official sourceCurrent patient administration and access information.
Open official sourceSource and label check completed August 1, 2026. Named clinical and operations review is still pending.
General information only. This page is not medical advice and does not replace diagnosis, treatment, or guidance from a licensed clinician.
Content was updated August 1, 2026 from the sources cited on this page. Medical guidance, prescribing information, medication availability, and insurance rules can change. A licensed clinician must confirm current information and determine each patient's eligibility, testing, treatment, administration setting, and follow-up. Call 911 for a medical emergency. Contact Nao Medical with a question or correction.
(917) 310-3371